Navigation Links
Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
Date:2/4/2008

ncer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a pivotal Phase II trial as a single agent in elderly patients with de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2006 and the Company's Form 10-Q for the quarter ended September 30, 2007. In particular, there can be no assurance as to the
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
3. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
4. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
5. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
6. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Access Pharmaceuticals Announces $2.7 Million New Equity
8. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
9. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
10. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
11. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... (PRWEB) September 23, 2014 Marktech Optoelectronics ... deep ultra violet emitters in the 280 nm wavelength ... UV emitters which range from 280nm to 405nm. These ... water sanitation as well as curing. Mark Campito, Marktech’s ... of special interest to manufacturers is that we offer ...
(Date:9/23/2014)... September 23, 2014 The Minnesota ... developer of cellular modems , platforms and ... the Startup category for the 2014 Tekne Awards. ... at the Minneapolis Convention Center on Thursday, November ... individuals who have shown superior technology innovation and ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Pearl's Premium ... breakthrough in drought tolerant grass seed this week with ... seed. The announcement coincides with the fact that it ... Spring as many believe. , As of the ... and favorable reviews by industry experts and the media ...
(Date:9/22/2014)... by researchers at the USC Viterbi School of ... 3-D microfluidic system quickly and cheaply by simply ... Microfluidic systems are used in many fields including ... volumes of fluids for use in applications such ... diagnostic testing, and synthetic chemistry. Traditionally, microfluidic devices ...
Breaking Biology Technology:Marktech Introduces its New Line of Deep UV Emitters 2NimbeLink Named Finalist for 15th Annual Tekne Awards 2NimbeLink Named Finalist for 15th Annual Tekne Awards 3Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5
... , Chemosaturation Demonstrates Clinically Meaningful Tumor ... Delcath Systems, Inc. (NASDAQ: DCTH ... tumor (mNET) cohort of the Company,s recently completed Phase ... and Interventional Radiological Society of Europe (CIRSE) congress ...
... N.Y. A new system to be installed ... enable exciting new research possibilities across the nation ... modeling and simulation, data science, high-performance computing, and ... million grant from the National Science Foundation (NSF) ...
... All ABC Members and Members of the Herb and ... that I inform you of the passing of our ... Saturday evening, September 10, per the tribute we have ... Director, American Botanical Council, Editor, HerbalGram & HerbClip ...
Cached Biology Technology:Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 2Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 3Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 4Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 5New supercomputer to boost Rensselaer leadership in high-performance computing 2New supercomputer to boost Rensselaer leadership in high-performance computing 3New supercomputer to boost Rensselaer leadership in high-performance computing 4Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 2Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 3Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 4Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 5Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 6Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 7
(Date:9/23/2014)... fragments called "jumping genes" that insert themselves into DNA ... phenomenon can result in age-related diseases such as cancer. ... that the "jumping genes" in mice become active as ... them in check in order to take on another ... Nature Communications , Professor of Biology Vera Gorbunova ...
(Date:9/22/2014)... new American Cancer Society study suggests that participants ... known as the food stamp program, had lower ... The authors say the findings emphasize the need ... quality of SNAP participants. , The SNAP program ... the resources to obtain a nutritionally adequate diet. ...
(Date:9/22/2014)... researchers are studying a potential new treatment that reverses ... which scars develop in the lungs and severely hamper ... which is delivered to lung tissue intravenously. In mouse ... fibrosis after several days. , The findings were ... Medicine . , "The mimic, when injected into the ...
Breaking Biology News(10 mins):A multi-function protein is key to stopping genomic parasites from 'jumping' 2Federal food program puts food on the table, but dietary quality could be improved 2Reversing the effects of pulmonary fibrosis 2
... the Upper Paraguay River and its tributaries, is the largest ... of organisms and it is an ark for large populations ... Pantanal fulfills a large range of ecosystem services that are ... seasonal floodplain system, plants, animals, and local human populations show ...
... cover all from the historical aspects of the beaver ... the development of reintroduced or recovering populations, consequences of ... beavers, relationship with animal and plant communities on land ... the high degree to which the beaver is able ...
... (Nicols Prez Hidalgo and M. Pilar Mier Durante) have ... Matsumura ) in Madrid, Spain from a photography displayed ... ) (ngel Umaran). The results have been published recently ... are available for free download. "This discovery is ...
Cached Biology News:
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
...
... versatile enclosures are designed ... or other process gas ... environment. HEPA filtration, heating/cooling, ... modules also available, along ...
... Staccato Series of systems provide fast and ... , genomics, proteomics and drug development laboratories. ... configurations; Mini Workstation Series, Application Series and ... Station is a remarkably compact system for ...
Biology Products: